Is IGF-1 LR3 safe for dogs?
The short answer
IGF-1 LR3 demands more caution than anything else on this site apart from the investigational oncology compounds. Two risks are concrete rather than theoretical: it can lower blood glucose enough to cause tremors or collapse, and because IGF-1 signalling drives cell proliferation it is contraindicated in any dog with known or suspected cancer. The mandatory four-week off-cycle exists to let receptor sensitivity recover. Canine evidence is Level V — mechanistic and extrapolated, not clinical.
The critical risks
⚠ Contraindicated with active cancer
IGF-1 signalling directly drives cell proliferation. In a dog with an existing malignancy that is precisely the wrong signal. Screening before use is mandatory, not advisory.
⚠ Hypoglycaemia risk
IGF-1 LR3 has insulin-like activity and can lower blood glucose. Tremors, disorientation, weakness, or collapse are emergencies. Blood glucose must be monitored, and diabetic dogs require direct veterinary management.
Additional cautions
Do not stack with MGF
MGF is a splice variant of the same gene and acts on overlapping pathways. Running both simultaneously compounds growth signalling without a clear rationale.
What the evidence base actually is
Safety claims are only as good as the studies behind them.
IGF-1 LR3 is a modified version of insulin-like growth factor 1, the hormone that mediates most of growth hormone's effects on muscle. The modification stops it binding to the carrier proteins that normally clear it, extending its active life from roughly twenty minutes to twenty or thirty hours. That potency is also the reason it demands the most caution of any compound here.
Dosing context
Safety is dose-dependent. These are the figures reported in the source literature.
| Weight class | Reported dose | Frequency | Duration | Studied for |
|---|---|---|---|---|
| Small / toy breedunder 22 lb (10 kg) | 10-40 mcg per day | Once daily | 4-6 weeks, then 4 weeks off | Muscle wasting, post-surgical recovery |
| Medium breed22–77 lb (10–35 kg) | 20-140 mcg per day | Once daily | 4-6 weeks, then 4 weeks off | Muscle wasting, sarcopenia, post-surgical recovery |
| Large / giant breedover 77 lb (35 kg) | 40-300 mcg per day | Once daily | 4-6 weeks, then 4 weeks off | Sarcopenia, muscle loss in senior dogs |
See the full IGF-1 LR3 profile for mechanism, protocol and monitoring detail.
Common questions
Is IGF-1 LR3 safe for dogs?+
IGF-1 LR3 demands more caution than anything else on this site apart from the investigational oncology compounds. Two risks are concrete rather than theoretical: it can lower blood glucose enough to cause tremors or collapse, and because IGF-1 signalling drives cell proliferation it is contraindicated in any dog with known or suspected cancer. The mandatory four-week off-cycle exists to let receptor sensitivity recover. Canine evidence is Level V — mechanistic and extrapolated, not clinical.
What are the side effects of IGF-1 LR3 in dogs?+
Contraindicated with active cancer: IGF-1 signalling directly drives cell proliferation. In a dog with an existing malignancy that is precisely the wrong signal. Screening before use is mandatory, not advisory. Hypoglycaemia risk: IGF-1 LR3 has insulin-like activity and can lower blood glucose. Tremors, disorientation, weakness, or collapse are emergencies. Blood glucose must be monitored, and diabetic dogs require direct veterinary management. Do not stack with MGF: MGF is a splice variant of the same gene and acts on overlapping pathways. Running both simultaneously compounds growth signalling without a clear rationale.
Can IGF-1 LR3 be given to a dog with cancer?+
No. IGF-1 LR3 is contraindicated in dogs with active or suspected cancer. IGF-1 signalling directly drives cell proliferation. In a dog with an existing malignancy that is precisely the wrong signal. Screening before use is mandatory, not advisory.
Does my dog need testing before starting IGF-1 LR3?+
No compound-specific genetic testing is established for IGF-1 LR3. Baseline bloodwork before starting, and repeat testing during a protocol, is standard practice and lets your veterinarian catch a problem before it becomes clinically apparent.
References
- 1.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16174871
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.